Clinical efficacy of entecavir in HBeAg-negative chronic hepatitis B with compensated cirrhosis

Han BenLi

doi:10.3969/j.issn.1001-5256.2016.08.018

Issue 8

Aug. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(8): 1525-1528

PDF( 1475 KB)

Clinical efficacy of entecavir in HBeAg-negative chronic hepatitis B with compensated cirrhosis

DOI: 10.3969/j.issn.1001-5256.2016.08.018

Han BenLi

Department of Hepatobiliary,Xiangyang Hospital of Traditional Chinese Medicine

Received Date: 2016-02-26
Published Date: 2016-08-20

Abstract

Abstract

Objective To investigate the clinical efficacy of 96- week entecavir( ETV) treatment for HBe Ag- negative chronic hepatitis B patients with compensated cirrhosis,as well as its effect on patients with different HBV DNA loads. Methods A total of 118 chronic hepatitis B patients with compensated cirrhosis who visited Xiangyang Hospital of Traditional Chinese Medicine from January 2009 to June 2013 were enrolled and all had Child- Pugh class A cirrhosis. According to HBV DNA load,these patients were divided into high- load group( group A,HBV DNA≥105copies / ml) and low- load group( group B,HBV DNA < 105 copies / ml). All the patients were treated with ETV 0. 5 mg / d for 96 weeks. Child- Pugh score was used to evaluate liver function before and after treatment,and the changes in alanine aminotransferase( ALT),albumin( Alb),and total bilirubin( TBil) after treatment were observed. Hyaluronic acid( HA),α2- macroglobulin,and liver stiffness measurement( LSM) were used to evaluate liver fibrosis. The t- test was used for comparison between groups,and a repeated- measures analysis of variance was used for comparison within one group and between groups at different time points. Chisquare test was applied for comparison of categorical data between the two groups. Results The two groups showed significant reductions in ALT,Alb,and TBil at weeks12 and 24 of treatment( all P < 0. 05),and the ALT normalization rate and HBV DNA clearance rate at weeks 24 and 48 of treatment showed significantly differences between the two groups( χ2= 9. 241,6. 428,11. 134,5. 139,all P < 0. 05). Both groups showed significant reductions in HA,α2- macroglobulin,and LSM after treatment( t = 2. 648,1. 921,4. 018,3. 166,2. 136,3. 461,all P < 0. 05). The incidence rates of complications such as variceal bleeding,ascites,and hepatocellular carcinoma showed no significant differences between the two groups( all P > 0.05). Conclusion In HBe Ag- negative chronic hepatitis B patients with compensated cirrhosis,ETV can significantly improve liver function,slow down the process of liver fibrosis and cirrhosis,and effectively reduce long- term complications.
- hepatitis B,
- chronic,
- hepatitis B e antigens,
- liver cirrhosis,
- entecavir

FullText(HTML)

References(15)

References

[1]GAO YZ,JIA SH,ZHAO LF,et al.Clinical efficacy of entecavir combined with Xinganbao capsules in treatment of liver cirrhosis among patients with chronic hepatitis B[J].J Clin Hepatol,2014,30(4):314-316.(in Chinese)高远征,贾素华,赵连峰,等.恩替卡韦联合心肝宝胶囊治疗慢性乙型肝炎肝硬化的疗效观察[J].临床肝胆病杂志,2014,30(4):314-316.

[2]LOK A,Mc MAHON BJ.Chronic hepatitis B:update 2009[J].Hepatology,2009,50(3):1-36.

[3]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.

[4]LIAW YF,KAO JH,PIRATVISUTH T,et al.Asian-Pacific consensus statement onthe management of chronic hepatitis B:a 2012update[J].Hepatol Int,2012,6(4):531-561.

[5]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.

[6]CHEN L,ZHOU XB,WEN DF,et al.Clinical features and liver pathology in chronic hepatitis B virus-infected patients with normal liver function[J].J Clin Hepatol,2015,31(9):1430-1433.(in Chinese)陈丽,周兴蓓,温丹凤,等.肝功能正常的慢性HBV感染者的临床特征及肝脏病理学分析[J].临床肝胆病杂志,2015,31(9):1430-1433.

[7]HUANG YN,WU H.Progress in the antiviral treatment of HBVrelated cirrhosis[J].Fudan Univ J Med Sci,2013,40(2):233-238.(in Chinese)黄英男,吴昊.乙型肝炎肝硬化抗病毒治疗研究进展[J].复旦学报:医学版,2013,40(2):233-238.

[8]WU Y,HAN L,YUAN YF,et al.Meta-analysis of telbivudine and lamivudine in the treatment of chronic hepatitis B[J].China Med Herald,2014,11(28):11-13,18.(in Chinese)吴岩,韩璐,原永芳,等.替比夫定和拉米夫定治疗慢性乙型肝炎的Meta分析[J].中国医药导报,2014,11(28):11-13,18.

[9]LIAW YF.Impact of therapy on the long term outcome of chronic hepatitis B[J].Clin Liver Dis,2013,17(3):413-423.

[10]MARCELLIN P,ASSELAH T.Long-term therapy for chronic hepatitis B:hepatitis B virus DNA suppression leading to cirrhosis reversal[J].J Gastroenterol Hepatol,2013,28(6):912-923.

[11]Chinese Society of Hepatology and Chinese Society of Infectious Diseases Chinese,Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.

[12]ZHANG YX,ZHANG JB.Clinical efficacy of modified prescription of pingweisini combined with entecavir on patients at decompensation stage of liver cirrhosis[J/CD].Chin J Liver Dis:Electronic Edition,2014,6(4):39-41.(in Chinese)张燕霞,张晋波.加减平胃四逆方联合恩替卡韦治疗乙型肝炎失代偿期肝硬化临床研究[J/CD].中国肝脏病杂志:电子版,2014,6(4):39-41.

[13]KUMADA T,TOYODA H,TADA T,et al.Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients:a propensity score analysis[J].J Hepatol,2013,58(3):427-433.

[14]CHANG ML,LIAW YF,HADZI YANNIS SJ.Systematic review:cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B[J].Aliment Pharmacol Ther,2015,42(3):243-257.

[15]KIM YJ,HO HC,SINN DH,et al.Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients[J].J Gastroenterol Hepatol,2012,27(2):306-312.

Relative Articles

[1]	Guozhi WU, Guohong WU, Xianglei ZHANG, Guangzhi DING, Lei WANG. Severe drug-induced hypersensitivity syndrome in patients with liver cirrhosis and epilepsy induced by lamotrigine: A case report[J]. Journal of Clinical Hepatology, 2021, 37(8): 1907-1908. doi: 10.3969/j.issn.1001-5256.2021.08.032
[2]	LI ZhengHong, DONG YuWei, LU LunGen. Risk factors,diagnosis,and updated classification of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2411-2414. doi: 10.3969/j.issn.1001-5256.2020.11.003
[3]	Ruan FangMing, Li BiMin. Risk factors for the formation of portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 182-185. doi: 10.3969/j.issn.1001-5256.2020.01.043
[4]	Wang CaiBin, Su Yang. Risk factors for posthepatectomy liver failure and related prevention and treatment methods[J]. Journal of Clinical Hepatology, 2020, 36(9): 2119-2124. doi: 10.3969/j.issn.1001-5256.2020.09.048
[5]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[6]	Ren DanDan, Liu Na, Zhou LuLu, Zhang Nan, Li ChunXia, Dong Bing, Xu GuangHua. Risk factors for hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1634-1638. doi: 10.3969/j.issn.1001-5256.2020.07.041
[7]	Bai Xue, Ma ZuoHong, Hao ZhiQiang, Fu XiBo, Jiao Ao, Shang Hai, Hua XiangDong. Research advances in the risk factors for microvascular invasion in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(11): 2578-2581. doi: 10.3969/j.issn.1001-5256.2019.11.042
[8]	Zhang Dan, Feng GuoHe. Current research status of nosocomial infection in patients with severe liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(1): 213-216. doi: 10.3969/j.issn.1001-5256.2019.01.047
[9]	Chang XiuJuan, Lu YinYing, Rong GuangHua, Liu Ze, Chen Yan, Xu GuiLin, Gao XuDong, Lou Min, Wang ChunPing, Yang YongPing, Ceng Zhen. Risk factors for vascular invasion of primary liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(5): 1038-1041. doi: 10.3969/j.issn.1001-5256.2018.05.022
[10]	Lin YunXia, He XiaoBin. Clinical features of drug-induced liver injury and related risk factors[J]. Journal of Clinical Hepatology, 2018, 34(6): 1237-1241. doi: 10.3969/j.issn.1001-5256.2018.06.021
[11]	Jie EnBo, Xuan FengHui, Sun XiaoDong, Sun DaWei, Lu: GuoYue. An analysis of risk factors for early complications after liver transplantation[J]. Journal of Clinical Hepatology, 2018, 34(6): 1282-1288. doi: 10.3969/j.issn.1001-5256.2018.06.030
[12]	Li Ying, Zhan Jing, Wang ZhongFeng. Prognostic factors for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2017, 33(3): 497-501. doi: 10.3969/j.issn.1001-5256.2017.03.020
[13]	Wang FengJiao, Liu MingJiang, Wu RuiHong, Niu JunQi. A multivariate logistic regression analysis of short-term prognosis of patients with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2017, 33(4): 711-714. doi: 10.3969/j.issn.1001-5256.2017.04.022
[14]	Chen BiHua, Zhang Wei, Wu Pei, Huang Ying. Research advances in risk factors for primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(12): 2088-2092. doi: 10.3969/j.issn.1001-5256.2015.12.024
[15]	Qiao LiNa, Dai GuangRong, Zhang Jin, Shen Ni. An epidemiological survey of prevalence and risk factors for fatty liver disease in adults residing in Yan'an,China[J]. Journal of Clinical Hepatology, 2015, 31(1): 82-87. doi: 10.3969/j.issn.1001-5256.2015.01.018
[16]	Ye ChuanTao, Wei Xin, Zhang Ying. Current status of research on liver innate immunity[J]. Journal of Clinical Hepatology, 2014, 30(9): 846-850. doi: 10.3969/j.issn.1001-5256.2014.09.003
[17]	Yu Zheng, Jia JiDong. Risk factors, diagnostic criteria, and drug discontinuation criteria for drug- induced liver injury[J]. Journal of Clinical Hepatology, 2013, 29(9): 674-677. doi: 10.3969/j.issn.1001-5256.2013.09.010
[18]	Wu XiaoQing, Wan Hong. Causes of liver failure and impact analysis of prognostic risk factors[J]. Journal of Clinical Hepatology, 2013, 29(4): 294-296+304.
[19]	Wang Hong, Wang YingMin, Zhang Bo. Prospective analysis of risk factors for the occurrence of hepatocellular carcinoma in patients with post-hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2007, 23(1): 34-35.
[20]	Wang Hong. Risk factors for patients with cirrhosis developed renal dysfunction[J]. Journal of Clinical Hepatology, 2004, 20(2): 101-102.

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 闫红会，张二娟，徐心红. 半坐卧位深部保留灌肠对肝性脑病患者的影响. 内蒙古医学杂志. 2023(11): 1386-1388+1391 .
Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2473) PDF downloads(463)

Clinical efficacy of entecavir in HBeAg-negative chronic hepatitis B with compensated cirrhosis

DOI: 10.3969/j.issn.1001-5256.2016.08.018

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(1)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Clinical efficacy of entecavir in HBeAg-negative chronic hepatitis B with compensated cirrhosis

DOI: 10.3969/j.issn.1001-5256.2016.08.018

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(1)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content